{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:47:30Z","timestamp":1782092850536,"version":"3.54.5"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Biofilms Microbiomes"],"DOI":"10.1038\/s41522-026-00972-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T10:23:52Z","timestamp":1776767032000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The microbial metabolome: remodeling the therapeutic landscape in hematologic malignancies"],"prefix":"10.1038","volume":"12","author":[{"given":"Liang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseer","family":"almajidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1805-6366","authenticated-orcid":false,"given":"Rushen","family":"Gafarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"972_CR1","doi-asserted-by":"crossref","unstructured":"Pinto-Merino, \u00c1. et al. Role of pharmacogenetics in the treatment of acute myeloid leukemia: systematic review and future perspectives. Pharmaceutics 14 (2022).","DOI":"10.3390\/pharmaceutics14030559"},{"key":"972_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00374-z","volume":"7","author":"QT Trac","year":"2023","unstructured":"Trac, Q. T. et al. Prediction model for drug response of acute myeloid leukemia patients. npj Precis. Oncol. 7, 32 (2023).","journal-title":"npj Precis. Oncol."},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae, A., van Rhee, F. & Al Hadidi, S. Perspectives on the Treatment Of Multiple Myeloma. Oncologist 29, 200\u2013212 (2024).","journal-title":"Oncologist"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1210\/me.2014-1108","volume":"28","author":"G Clarke","year":"2014","unstructured":"Clarke, G. et al. Minireview: Gut microbiota: the neglected endocrine organ. Mol. Endocrinol. 28, 1221\u20131238 (2014).","journal-title":"Mol. Endocrinol."},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41392-024-01946-6","volume":"9","author":"Z Ma","year":"2024","unstructured":"Ma, Z. et al. A systematic framework for understanding the microbiome in human health and disease: from basic principles to clinical translation. Signal Transduct. Target. Ther. 9, 237 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-med-060513-093205","volume":"66","author":"JM Brown","year":"2015","unstructured":"Brown, J. M. & Hazen, S. L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu. Rev. Med. 66, 343\u2013359 (2015).","journal-title":"Annu. Rev. Med."},{"key":"972_CR7","doi-asserted-by":"publisher","first-page":"9383","DOI":"10.3390\/app14209383","volume":"14","author":"L Pires","year":"2024","unstructured":"Pires, L. et al. Gut microbiota as an endocrine organ: unveiling its role in human physiology and health. Appl. Sci. 14, 9383 (2024).","journal-title":"Appl. Sci."},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"17100","DOI":"10.3390\/ijms242317100","volume":"24","author":"N Torres-Carrillo","year":"2023","unstructured":"Torres-Carrillo, N. et al. Pharmacomicrobiomics and drug\u2013infection interactions: the impact of commensal, symbiotic and pathogenic microorganisms on a host response to drug therapy. Int. J. Mol. Sci. 24, 17100 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-023-01619-w","volume":"8","author":"Q Zhao","year":"2023","unstructured":"Zhao, Q. et al. Drug-microbiota interactions: an emerging priority for precision medicine. Signal Transduct. Target. Ther. 8, 386 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1073\/pnas.1918095117","volume":"117","author":"AP Bhatt","year":"2020","unstructured":"Bhatt, A. P. et al. Targeted inhibition of gut bacterial \u03b2-glucuronidase activity enhances anticancer drug efficacy. Proc. Natl. Acad. Sci. USA 117, 7374\u20137381 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"972_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/gmic.27915","volume":"5","author":"HJ Haiser","year":"2014","unstructured":"Haiser, H. J. et al. Mechanistic insight into digoxin inactivation by Eggerthella lenta augments our understanding of its pharmacokinetics. Gut Microbes 5, 233\u2013238 (2014).","journal-title":"Gut Microbes"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"e33953","DOI":"10.7554\/eLife.33953","volume":"7","author":"N Koppel","year":"2018","unstructured":"Koppel, N. et al. Discovery and characterization of a prevalent human gut bacterial enzyme sufficient for the inactivation of a family of plant toxins. eLife 7, e33953 (2018).","journal-title":"eLife"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425255.2024.2407616","volume":"21","author":"S Kamath","year":"2025","unstructured":"Kamath, S. & Joyce, P. A critical need for \u2018gut neutrality\u2019: mitigating adverse drug-microbiome interactions. Expert Opin. Drug Metab. Toxicol. 21, 1\u20134 (2025).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s42003-021-01815-w","volume":"4","author":"H-Y Lin","year":"2021","unstructured":"Lin, H.-Y. et al. Entropy-driven binding of gut bacterial \u03b2-glucuronidase inhibitors ameliorates irinotecan-induced toxicity. Commun. Biol. 4, 280 (2021).","journal-title":"Commun. Biol."},{"key":"972_CR15","doi-asserted-by":"crossref","unstructured":"Hu, E., Li, Z., Li, T., Yang, X., Ding, R., Jiang, H.,... Wang, Y. (2023). A novel microbial and hepatic biotransformation-integrated network pharmacology strategy explores the therapeutic mechanisms of bioactive herbal products in neurological diseases: the effects of Astragaloside IV on intracerebral hemorrhage as an example. Chinese Medicine, 18(1), 40. doi: 10.1186\/s13020-023-00745-5","DOI":"10.1186\/s13020-023-00745-5"},{"key":"972_CR16","doi-asserted-by":"publisher","first-page":"1675677","DOI":"10.3389\/fimmu.2025.1675677","volume":"16","author":"H Duan","year":"2025","unstructured":"Duan, H. et al. Microbial metabolites and their influence on the tumor microenvironment. Front. Immunol. 16, 1675677 (2025).","journal-title":"Front. Immunol."},{"key":"972_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager, L. F. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369, 1481\u20131489 (2020).","journal-title":"Science"},{"key":"972_CR18","doi-asserted-by":"crossref","unstructured":"Broecker, F. & Moelling, K. The roles of the virome in cancer. Microorganisms 9, 2538 (2021).","DOI":"10.3390\/microorganisms9122538"},{"key":"972_CR19","doi-asserted-by":"crossref","unstructured":"Cao, Z. et al. The gut virome: a new microbiome component in health and disease. eBioMedicine 81, 104113 (2022).","DOI":"10.1016\/j.ebiom.2022.104113"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fimmu.2020.591088","volume":"11","author":"M Irfan","year":"2020","unstructured":"Irfan, M., Delgado, R. Z. R. & Frias-Lopez, J. The oral microbiome and cancer. Front. Immunol. 11, 2020 (2020).","journal-title":"Front. Immunol."},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2022.09.005","volume":"185","author":"L Narunsky-Haziza","year":"2022","unstructured":"Narunsky-Haziza, L. et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185, 3789\u20133806.e17 (2022).","journal-title":"Cell"},{"key":"972_CR22","doi-asserted-by":"crossref","unstructured":"Wang, Y.-F. et al. Short-chain fatty acids: microbial metabolites bridging tumor immunity and cancer therapy through microenvironment modulation. Cancer Adv. 8 (2025). pg 1-20.","DOI":"10.53388\/2025825012"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/icb.2017.8","volume":"95","author":"D Allard","year":"2017","unstructured":"Allard, D., Turcotte, M. & Stagg, J. Targeting A2 adenosine receptors in cancer. Immunol. Cell Biol. 95, 333\u2013339 (2017).","journal-title":"Immunol. Cell Biol."},{"key":"972_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nri.2016.4","volume":"16","author":"C Cekic","year":"2016","unstructured":"Cekic, C. & Linden, J. Purinergic regulation of the immune system. Nat. Rev. Immunol. 16, 177\u2013192 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fimmu.2020.570041","volume":"11","author":"JM Steingold","year":"2020","unstructured":"Steingold, J. M. & Hatfield, S. M. Targeting hypoxia-A2A adenosinergic immunosuppression of antitumor T cells during cancer immunotherapy. Front. Immunol. 11, 2020 (2020).","journal-title":"Front. Immunol."},{"key":"972_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-020-00465-z","volume":"20","author":"L Bird","year":"2020","unstructured":"Bird, L. Microbial metabolite boosts immunotherapy. Nat. Rev. Immunol. 20, 648\u2013649 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.medj.2025.100773","volume":"6","author":"M Perl","year":"2025","unstructured":"Perl, M. et al. Microbiota-derived metabolites: key modulators of cancer immunotherapies. Med. 6, 100773 (2025).","journal-title":"Med."},{"key":"972_CR28","doi-asserted-by":"crossref","unstructured":"Sun, D. et al. Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies. Int. Immunopharmacol. 144, 113392 (2025).","DOI":"10.1016\/j.intimp.2024.113392"},{"key":"972_CR29","doi-asserted-by":"crossref","unstructured":"Feng, C. et al. Precisely Tailoring Molecular Structure of Doxorubicin Prodrugs to Enable Stable Nanoassembly, Rapid Activation, and Potent Antitumor Effect. Pharmaceutics 16(12), 1582 (2024).","DOI":"10.3390\/pharmaceutics16121582"},{"key":"972_CR30","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1900623","volume":"382","author":"JU Peled","year":"2020","unstructured":"Peled, J. U. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 382, 822\u2013834 (2020).","journal-title":"N. Engl. J. Med."},{"key":"972_CR31","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Yang, Q., Yang, Q., He, Y. & Zhou, W. Intestinal microbes and hematological malignancies. Cancers 15, 2284 (2023).","DOI":"10.3390\/cancers15082284"},{"key":"972_CR32","doi-asserted-by":"crossref","unstructured":"Jafarabadi, M., Khaledi, A. Escherichia Coli Bloodstream Infections and Associated Antibiotic Resistance Pattern in Hematological Malignancy Populations, A Global Systematic Review. Eurasian J. Med. Oncol. 8(1), 15\u201323 (2024).","DOI":"10.14744\/ejmo.2024.79645"},{"key":"972_CR33","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1182\/blood.2023020026","volume":"142","author":"R Masetti","year":"2023","unstructured":"Masetti, R. et al. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children. Blood 142, 1387\u20131398 (2023).","journal-title":"Blood"},{"key":"972_CR34","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fmicb.2023.1185787","volume":"14","author":"P Guevara-Ram\u00edrez","year":"2023","unstructured":"Guevara-Ram\u00edrez, P. et al. Role of the gut microbiota in hematologic cancer. Front. Microbiol. 14, 2023 (2023).","journal-title":"Front. Microbiol."},{"key":"972_CR35","first-page":"2024","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. The impact of gut microbial signals on hematopoietic stem cells and the bone marrow microenvironment. Front. Immunol. 15, 2024 (2024).","journal-title":"Front. Immunol."},{"key":"972_CR36","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.stem.2021.12.009","volume":"29","author":"D Zhang","year":"2022","unstructured":"Zhang, D. et al. The microbiota regulates hematopoietic stem cell fate decisions by controlling iron availability in bone marrow. Cell Stem Cell 29, 232\u2013247.e7 (2022).","journal-title":"Cell Stem Cell"},{"key":"972_CR37","doi-asserted-by":"publisher","first-page":"e110712","DOI":"10.15252\/embj.2022110712","volume":"41","author":"M Sezaki","year":"2022","unstructured":"Sezaki, M. et al. Hematopoietic stem and progenitor cells integrate microbial signals to promote post-inflammation gut tissue repair. EMBO J. 41, e110712 (2022).","journal-title":"EMBO J."},{"key":"972_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.immuni.2006.04.008","volume":"24","author":"Y Nagai","year":"2006","unstructured":"Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24, 801\u2013812 (2006).","journal-title":"Immunity"},{"key":"972_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.stem.2017.06.013","volume":"21","author":"H Takizawa","year":"2017","unstructured":"Takizawa, H. et al. Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness. Cell Stem Cell 21, 225\u2013240.e5 (2017).","journal-title":"Cell Stem Cell"},{"key":"972_CR40","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.3748\/wjg.v27.i45.7792","volume":"27","author":"Q Le Bastard","year":"2021","unstructured":"Le Bastard, Q., Chevallier, P. & Montassier, E. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft vs host disease. World J. Gastroenterol. 27, 7792\u20137800 (2021).","journal-title":"World J. Gastroenterol."},{"key":"972_CR41","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.bbmt.2017.12.670","volume":"24","author":"L Romick-Rosendale","year":"2018","unstructured":"Romick-Rosendale, L. et al. Short chain fatty acids are reduced after hematopoietic stem cell transplant in humans and are associated with modifications of the gut microbiome. Biol. Blood Marrow Transplant. 24, S87\u2013S88 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"972_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"972_CR43","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"972_CR44","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"972_CR45","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.immuni.2018.04.022","volume":"48","author":"A Trompette","year":"2018","unstructured":"Trompette, A. et al. Dietary fiber confers protection against flu by shaping Ly6c(-) patrolling monocyte hematopoiesis and CD8(+) T cell metabolism. Immunity 48, 992\u20131005.e8 (2018).","journal-title":"Immunity"},{"key":"972_CR46","doi-asserted-by":"publisher","first-page":"14648","DOI":"10.1021\/acsomega.3c05846","volume":"9","author":"A Verma","year":"2024","unstructured":"Verma, A. et al. Short-chain fatty acid (SCFA) as a connecting link between microbiota and gut-lung axis-a potential therapeutic intervention to improve lung health. ACS Omega 9, 14648\u201314671 (2024).","journal-title":"ACS Omega"},{"key":"972_CR47","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602\u2013609 (2021).","journal-title":"Science"},{"key":"972_CR48","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595\u2013602 (2021).","journal-title":"Science"},{"key":"972_CR49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrmicro.2018.12","volume":"16","author":"A York","year":"2018","unstructured":"York, A. Gut microbiota sways response to cancer immunotherapy. Nat. Rev. Microbiol. 16, 121\u2013121 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"972_CR50","first-page":"933","volume":"106","author":"I Henig","year":"2021","unstructured":"Henig, I., Yehudai-Ofir, D. & Zuckerman, T. The clinical role of the gut microbiome and fecal microbiota transplantation in allogeneic stem cell transplantation. Haematologica 106, 933\u2013946 (2021).","journal-title":"Haematologica"},{"key":"972_CR51","doi-asserted-by":"crossref","unstructured":"Golusinska-Kardach, E., Yadav, H., Jain, S., Masternak, M. M. & Golusinski, W. The oral microbiome and head and neck cancer: a narrative review. Cancers 17, 2736 (2025).","DOI":"10.3390\/cancers17172736"},{"key":"972_CR52","doi-asserted-by":"publisher","first-page":"ofaf213","DOI":"10.1093\/ofid\/ofaf213","volume":"12","author":"K Hosszu-Fellous","year":"2025","unstructured":"Hosszu-Fellous, K. et al. Blood virome after allogeneic hematopoietic stem cell transplantation. Open Forum Infect. Dis. 12, ofaf213 (2025).","journal-title":"Open Forum Infect. Dis."},{"key":"972_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminhematol.2020.05.001","volume":"57","author":"J Legoff","year":"2020","unstructured":"Legoff, J., Michonneau, D. & Socie, G. The virome in hematology\u2014stem cell transplantation and beyond. Semin. Hematol. 57, 19\u201325 (2020).","journal-title":"Semin. Hematol."},{"key":"972_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/ol.2023.14128","volume":"26","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Influence of tumor mycobiome on cancer pathogenesis (Review). Oncol. Lett. 26, 541 (2023).","journal-title":"Oncol. Lett."},{"key":"972_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-245","volume":"8","author":"V de Cr\u00e9cy-Lagard","year":"2007","unstructured":"de Cr\u00e9cy-Lagard, V. et al. Comparative genomics of bacterial and plant folate synthesis and salvage: predictions and validations. BMC Genom. 8, 245 (2007).","journal-title":"BMC Genom."},{"key":"972_CR56","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3389\/fmicb.2019.02305","volume":"10","author":"MA Engevik","year":"2019","unstructured":"Engevik, M. A. et al. Microbial metabolic capacity for intestinal folate production and modulation of host folate receptors. Front Microbiol 10, 2305 (2019).","journal-title":"Front Microbiol"},{"key":"972_CR57","doi-asserted-by":"crossref","unstructured":"Villa Soto, V.S., Degraeve, A.L., Heath, C.M., Orellana, D.A., Reilly, E.R., Mukherjee, M., Brockert, J.G., Dumlao, D.S., Blank, R.B., Perlmutter, N. and Yu, S., 2025. The gut microbiome shapes pharmacology and treatment outcomes for a key anti-inflammatory therapy. bioRxiv, pp.2025-06.","DOI":"10.1101\/2025.06.26.661733"},{"key":"972_CR58","doi-asserted-by":"publisher","first-page":"789334","DOI":"10.3389\/fimmu.2021.789334","volume":"12","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. Pharmacomicrobiology of methotrexate in rheumatoid arthritis: gut microbiome as predictor of therapeutic response. Front. Immunol. 12, 789334 (2021).","journal-title":"Front. Immunol."},{"key":"972_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","volume":"179","author":"ID Wilson","year":"2017","unstructured":"Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 179, 204\u2013222 (2017).","journal-title":"Transl. Res."},{"key":"972_CR60","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ebiom.2018.06.029","volume":"33","author":"B Zhou","year":"2018","unstructured":"Zhou, B. et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota. EBioMedicine 33, 122\u2013133 (2018).","journal-title":"EBioMedicine"},{"key":"972_CR61","doi-asserted-by":"crossref","unstructured":"Verdegaal, A. A. & Goodman, A. L. Integrating the gut microbiome and pharmacology. Sci. Transl. Med. 16, eadg8357 (2024).","DOI":"10.1126\/scitranslmed.adg8357"},{"key":"972_CR62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/art.41622","volume":"73","author":"A Artacho","year":"2021","unstructured":"Artacho, A. et al. The pretreatment gut microbiome is associated with lack of response to methotrexate in new-onset rheumatoid arthritis. Arthritis Rheumatol. 73, 931\u2013942 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"972_CR63","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.chom.2020.12.008","volume":"29","author":"RR Nayak","year":"2021","unstructured":"Nayak, R. R. et al. Methotrexate impacts conserved pathways in diverse human gut bacteria leading to decreased host immune activation. Cell Host Microbe 29, 362\u2013377.e11 (2021).","journal-title":"Cell Host Microbe"},{"key":"972_CR64","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/S0006-2952(03)00417-9","volume":"66","author":"A El Fadili","year":"2003","unstructured":"El Fadili, A. et al. Effect of polyglutamylation of methotrexate on its accumulation and the development of resistance in the protozoan parasite Leishmania. Biochem. Pharmacol. 66, 999\u20131008 (2003).","journal-title":"Biochem. Pharmacol."},{"key":"972_CR65","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1021\/acs.jproteome.0c00230","volume":"19","author":"MPM Letertre","year":"2020","unstructured":"Letertre, M. P. M. et al. A two-way interaction between methotrexate and the gut microbiota of male Sprague-Dawley rats. J. Proteome Res. 19, 3326\u20133339 (2020).","journal-title":"J. Proteome Res."},{"key":"972_CR66","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fmicb.2022.1101144","volume":"13","author":"S Mazhar","year":"2023","unstructured":"Mazhar, S. et al. In vitro and in silico assessment of probiotic and functional properties of Bacillus subtilis DE111\u00ae. Front. Microbiol. 13, 2022 (2023).","journal-title":"Front. Microbiol."},{"key":"972_CR67","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.chom.2024.06.002","volume":"32","author":"T Yu","year":"2024","unstructured":"Yu, T. et al. Multi-omics signatures reveal genomic and functional heterogeneity of Cutibacterium acnes in normal and diseased skin. Cell Host Microbe 32, 1129\u20131146.e8 (2024).","journal-title":"Cell Host Microbe"},{"key":"972_CR68","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3389\/fmicb.2023.1107976","volume":"14","author":"HEF Becker","year":"2023","unstructured":"Becker, H. E. F. et al. Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front. Microbiol. 14, 2023 (2023).","journal-title":"Front. Microbiol."},{"key":"972_CR69","doi-asserted-by":"crossref","unstructured":"Chen, Y. C. et al. The impact of gut microbiota changes on methotrexate-induced neurotoxicity in developing young rats. Biomedicines 12, 908 (2024).","DOI":"10.3390\/biomedicines12040908"},{"key":"972_CR70","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1871525715666170529091921","volume":"15","author":"C Asadov","year":"2017","unstructured":"Asadov, C., Aliyeva, G. & Mustafayeva, K. Thiopurine S-methyltransferase as a pharmacogenetic biomarker: significance of testing and review of major methods. Cardiovasc. Hematol. Agents Med. Chem. 15, 23\u201330 (2017).","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"972_CR71","unstructured":"Dean, L. & Kane, M. Mercaptopurine Therapy and TPMT and NUDT15 Genotype (Medical Genetics Summaries, 2012)."},{"key":"972_CR72","doi-asserted-by":"publisher","first-page":"879170","DOI":"10.3389\/fphar.2022.879170","volume":"13","author":"S Lazarevic","year":"2022","unstructured":"Lazarevic, S. et al. Gut microbiota metabolism of azathioprine: a new hallmark for personalized drug-targeted therapy of chronic inflammatory bowel disease. Front. Pharmacol. 13, 879170 (2022).","journal-title":"Front. Pharmacol."},{"key":"972_CR73","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jmb.2003.08.039","volume":"333","author":"TH Scheuermann","year":"2003","unstructured":"Scheuermann, T. H., Lolis, E. & Hodsdon, M. E. Tertiary structure of thiopurine methyltransferase from Pseudomonas syringae, a bacterial orthologue of a polymorphic, drug-metabolizing enzyme. J. Mol. Biol. 333, 573\u2013585 (2003).","journal-title":"J. Mol. Biol."},{"key":"972_CR74","doi-asserted-by":"publisher","first-page":"101153","DOI":"10.1016\/j.xcrm.2023.101153","volume":"4","author":"Y Yan","year":"2023","unstructured":"Yan, Y. et al. Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability. Cell Rep. Med. 4, 101153 (2023).","journal-title":"Cell Rep. Med."},{"key":"972_CR75","doi-asserted-by":"crossref","unstructured":"Jantararoungtong, T. et al. TPMT*3C as a predictor of 6-mercaptopurine-induced myelotoxicity in Thai children with acute lymphoblastic leukemia. J. Pers. Med. 11, 783 (2021).","DOI":"10.3390\/jpm11080783"},{"key":"972_CR76","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.immuni.2016.09.009","volume":"45","author":"R Daill\u00e8re","year":"2016","unstructured":"Daill\u00e8re, R. et al. Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects. Immunity 45, 931\u2013943 (2016).","journal-title":"Immunity"},{"key":"972_CR77","doi-asserted-by":"publisher","first-page":"520","DOI":"10.6004\/jadpro.2023.14.6.5","volume":"14","author":"E Kachur","year":"2023","unstructured":"Kachur, E. et al. Post-transplant cyclophosphamide for the prevention of graft-vs.-host disease in allogeneic hematopoietic cell transplantation: a guide to management for the advanced practitioner. J. Adv. Pract. Oncol. 14, 520\u2013532 (2023).","journal-title":"J. Adv. Pract. Oncol."},{"key":"972_CR78","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","volume":"23","author":"M Scurr","year":"2017","unstructured":"Scurr, M. et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin. Cancer Res. 23, 6771\u20136780 (2017).","journal-title":"Clin. Cancer Res."},{"key":"972_CR79","first-page":"2024","volume":"15","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Different evasion strategies in multiple myeloma. Front. Immunol. 15, 2024 (2024).","journal-title":"Front. Immunol."},{"key":"972_CR80","doi-asserted-by":"publisher","first-page":"111572","DOI":"10.1016\/j.mce.2022.111572","volume":"546","author":"KJ O\u2019Riordan","year":"2022","unstructured":"O\u2019Riordan, K. J. et al. Short chain fatty acids: microbial metabolites for gut-brain axis signalling. Mol. Cell. Endocrinol. 546, 111572 (2022).","journal-title":"Mol. Cell. Endocrinol."},{"key":"972_CR81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fendo.2020.00025","volume":"11","author":"YP Silva","year":"2020","unstructured":"Silva, Y. P., Bernardi, A. & Frozza, R. L. The role of short-chain fatty acids from gut microbiota in gut-brain communication. Front. Endocrinol. 11, 25 (2020).","journal-title":"Front. Endocrinol."},{"key":"972_CR82","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","volume":"28","author":"UA Shah","year":"2022","unstructured":"Shah, U. A. et al. Sustained minimal residual disease negativity in multiple myeloma is associated with stool butyrate and healthier plant-based diets. Clin. Cancer Res. 28, 5149\u20135155 (2022).","journal-title":"Clin. Cancer Res."},{"key":"972_CR83","doi-asserted-by":"publisher","first-page":"741376","DOI":"10.3389\/fonc.2021.741376","volume":"11","author":"M Jasinski","year":"2021","unstructured":"Jasinski, M., Bilinski, J. & Basak, G. W. The role of the gut microbiome in pathogenesis, biology, and treatment of plasma cell dyscrasias. Front. Oncol. 11, 741376 (2021).","journal-title":"Front. Oncol."},{"key":"972_CR84","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1126\/science.aaw7479","volume":"364","author":"E Ansaldo","year":"2019","unstructured":"Ansaldo, E. et al. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science 364, 1179\u20131184 (2019).","journal-title":"Science"},{"key":"972_CR85","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.3390\/ijms24032769","volume":"24","author":"D Dora","year":"2023","unstructured":"Dora, D. et al. Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy. Int. J. Mol. Sci. 24, 2769 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"972_CR86","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/gutjnl-2018-317220","volume":"68","author":"RZ Gharaibeh","year":"2019","unstructured":"Gharaibeh, R. Z. & Jobin, C. Microbiota and cancer immunotherapy: in search of microbial signals. Gut 68, 385\u2013388 (2019).","journal-title":"Gut"},{"key":"972_CR87","doi-asserted-by":"publisher","first-page":"e3301","DOI":"10.1002\/hon.3301","volume":"42","author":"B Casadei","year":"2024","unstructured":"Casadei, B. et al. Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors\u2014the MicroLinf study. Hematol. Oncol. 42, e3301 (2024).","journal-title":"Hematol. Oncol."},{"key":"972_CR88","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315\u2013324 (2022).","journal-title":"Nat. Med."},{"key":"972_CR89","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","volume":"12","author":"M Zhang","year":"2023","unstructured":"Zhang, M., Liu, J. & Xia, Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Exp. Hematol. Oncol. 12, 84 (2023).","journal-title":"Exp. Hematol. Oncol."},{"key":"972_CR90","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2014-02-554725","volume":"124","author":"Y Taur","year":"2014","unstructured":"Taur, Y. et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood 124, 1174\u20131182 (2014).","journal-title":"Blood"},{"key":"972_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06797-5","volume":"23","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan, H. et al. The microbiome in graft-versus-host disease: a tale of two ecosystems. J. Transl. Med. 23, 832 (2025).","journal-title":"J. Transl. Med."},{"key":"972_CR92","doi-asserted-by":"publisher","first-page":"e6799","DOI":"10.1002\/cam4.6799","volume":"13","author":"X Yue","year":"2024","unstructured":"Yue, X. et al. Gut microbiota, microbiota-derived metabolites, and graft-versus-host disease. Cancer Med. 13, e6799 (2024).","journal-title":"Cancer Med."},{"key":"972_CR93","doi-asserted-by":"crossref","unstructured":"Guo, H. et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science 370, eaay9097 (2020).","DOI":"10.1126\/science.aay9097"},{"key":"972_CR94","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s10020-024-00873-0","volume":"30","author":"L Lu","year":"2024","unstructured":"Lu, L. et al. Microbiome in radiotherapy: an emerging approach to enhance treatment efficacy and reduce tissue injury. Mol. Med. 30, 105 (2024).","journal-title":"Mol. Med."},{"key":"972_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70481","volume":"15","author":"S Ma","year":"2025","unstructured":"Ma, S. et al. Targeting gut microbiota and metabolites in cancer radiotherapy. Clin. Transl. Med. 15, e70481 (2025).","journal-title":"Clin. Transl. Med."},{"key":"972_CR96","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-025-02142-6","volume":"13","author":"OM Drevland","year":"2025","unstructured":"Drevland, O. M. et al. Microbiome-derived reactivation of mycophenolate explains variations in enterohepatic recirculation in kidney transplant recipients. Microbiome 13, 169 (2025).","journal-title":"Microbiome"},{"key":"972_CR97","doi-asserted-by":"crossref","unstructured":"Taylor, M. R. et al. Vancomycin relieves mycophenolate mofetil\u2013induced gastrointestinal toxicity by eliminating gut bacterial \u03b2-glucuronidase activity. Sci Adv. 5, eaax2358 (2019).","DOI":"10.1126\/sciadv.aax2358"},{"key":"972_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-023-01578-y","volume":"11","author":"AL Degraeve","year":"2023","unstructured":"Degraeve, A. L. et al. Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1. Microbiome 11, 138 (2023).","journal-title":"Microbiome"},{"key":"972_CR99","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1124\/dmd.118.084772","volume":"47","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Commensal gut bacteria convert the immunosuppressant tacrolimus to less potent metabolites. Drug Metab. Dispos. 47, 194\u2013202 (2019).","journal-title":"Drug Metab. Dispos."},{"key":"972_CR100","doi-asserted-by":"crossref","unstructured":"Saqr, A., Cheng, S., Al-Kofahi, M., Staley, C. & Jacobson, P. A. Microbiome-informed dosing: exploring gut microbial communities impact on mycophenolate enterohepatic circulation and therapeutic target achievement. Clin. Pharmacol. Ther. 118, 1477\u20131488 (2025).","DOI":"10.1002\/cpt.3740"},{"key":"972_CR101","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/pharmaceutics15061734","volume":"15","author":"N Dukaew","year":"2023","unstructured":"Dukaew, N. et al. Gut microbiota-mediated pharmacokinetic drug\u2013drug interactions between mycophenolic acid and trimethoprim-sulfamethoxazole in humans. Pharmaceutics 15, 1734 (2023).","journal-title":"Pharmaceutics"},{"key":"972_CR102","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/ni.3400","volume":"17","author":"ND Mathewson","year":"2016","unstructured":"Mathewson, N. D. et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat. Immunol. 17, 505\u2013513 (2016).","journal-title":"Nat. Immunol."},{"key":"972_CR103","doi-asserted-by":"publisher","first-page":"204062072412376","DOI":"10.1177\/20406207241237602","volume":"15","author":"X Song","year":"2024","unstructured":"Song, X. et al. Research advances on short-chain fatty acids in gastrointestinal acute graft-versus-host disease. Ther. Adv. Hematol. 15, 20406207241237602 (2024).","journal-title":"Ther. Adv. Hematol."},{"key":"972_CR104","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","volume":"8","author":"F Perna","year":"2024","unstructured":"Perna, F. et al. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. Blood Adv. 8, 4348\u20134358 (2024).","journal-title":"Blood Adv."},{"key":"972_CR105","first-page":"2024","volume":"15","author":"P-F Zhang","year":"2024","unstructured":"Zhang, P.-F. & Xie, D. Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope? Front. Immunol. 15, 2024 (2024).","journal-title":"Front. Immunol."},{"key":"972_CR106","doi-asserted-by":"publisher","first-page":"e70334","DOI":"10.1002\/mco2.70334","volume":"6","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. Gut Microbiome and metabolome dynamics as predictors of clinical outcomes in hematopoietic stem cell transplantation. MedComm 6, e70334 (2025) (2020).","journal-title":"MedComm"},{"key":"972_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90976-z","volume":"11","author":"KJ Skaarud","year":"2021","unstructured":"Skaarud, K. J. et al. Mortality and microbial diversity after allogeneic hematopoietic stem cell transplantation: secondary analysis of a randomized nutritional intervention trial. Sci. Rep. 11, 11593 (2021).","journal-title":"Sci. Rep."},{"key":"972_CR108","doi-asserted-by":"crossref","unstructured":"Qian, Y., Wang, Q., Yin, L., & Lu, A. (2025). CF-DTI: coarse-to-fine feature extraction for enhanced drug-target interaction prediction. Health Information Science and Systems, 13(1), 55. doi: 10.1007\/s13755-025-00370-6","DOI":"10.1007\/s13755-025-00370-6"},{"key":"972_CR109","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1182\/bloodadvances.2024014476","volume":"9","author":"S Saha","year":"2025","unstructured":"Saha, S. et al. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv. 9, 3429\u20133440 (2025).","journal-title":"Blood Adv."},{"key":"972_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-025-01507-8","volume":"17","author":"O Shtossel","year":"2025","unstructured":"Shtossel, O. et al. Microbiome-based prediction of allogeneic hematopoietic stem cell transplantation outcome. Genome Med. 17, 80 (2025).","journal-title":"Genome Med."},{"key":"972_CR111","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1182\/bloodadvances.2024015703","volume":"9","author":"S Andersen","year":"2025","unstructured":"Andersen, S. et al. Prebiotic fiber enteral supplementation after allogeneic transplantation: feasibility and impact on the microbiome. Blood Adv. 9, 4167\u20134179 (2025).","journal-title":"Blood Adv."},{"key":"972_CR112","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.trim.2023.101836","volume":"78","author":"E Yazdandoust","year":"2023","unstructured":"Yazdandoust, E. et al. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation. Transpl. Immunol. 78, 101836 (2023).","journal-title":"Transpl. Immunol."},{"key":"972_CR113","doi-asserted-by":"crossref","unstructured":"Guo, L., Ding, J., & Zhou, W. Harnessing bacteria for tumor therapy: Current advances and challenges. Chinese Chem. Lett. 35(2), 108557 (2024).","DOI":"10.1016\/j.cclet.2023.108557"},{"key":"972_CR114","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.1182\/blood-2003-11-3769","volume":"103","author":"A Gerbitz","year":"2004","unstructured":"Gerbitz, A. et al. Probiotic effects on experimental graft-versus-host disease: let them eat yogurt. Blood 103, 4365\u20134367 (2004).","journal-title":"Blood"},{"key":"972_CR115","doi-asserted-by":"crossref","unstructured":"Gorshein, E. et al. Lactobacillus rhamnosus GG probiotic enteric regimen does not appreciably alter the gut microbiome or provide protection against GVHD after allogeneic hematopoietic stem cell transplantation. Clin. Transplant 31 (2017). p.e12947","DOI":"10.1111\/ctr.12947"},{"key":"972_CR116","doi-asserted-by":"crossref","unstructured":"Ebigbo, N. et al. Optimizing precision probiotics for mitigating graft-versus-host disease. Microorganisms 13, 706 (2025).","DOI":"10.3390\/microorganisms13040706"},{"key":"972_CR117","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1172\/JCI125797","volume":"129","author":"DN Fredricks","year":"2019","unstructured":"Fredricks, D. N. The gut microbiota and graft-versus-host disease. J. Clin. Investig. 129, 1808\u20131817 (2019).","journal-title":"J. Clin. Investig."},{"key":"972_CR118","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa2106516","volume":"386","author":"P Feuerstadt","year":"2022","unstructured":"Feuerstadt, P. et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile Infection. N. Engl. J. Med. 386, 220\u2013229 (2022).","journal-title":"N. Engl. J. Med."},{"key":"972_CR119","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1007\/s40121-024-01007-z","volume":"13","author":"CS Kraft","year":"2024","unstructured":"Kraft, C. S. et al. Integrated safety and efficacy analyses of Phase 3 trials of a microbiome therapeutic for recurrent CDI. Infect. Dis. Ther. 13, 2105\u20132121 (2024).","journal-title":"Infect. Dis. Ther."},{"key":"972_CR120","doi-asserted-by":"crossref","unstructured":"Khanna, S. et al. SER-109: an oral investigational microbiome therapeutic for patients with recurrent Clostridioides difficile infection (rCDI). Antibiotics 11, 1234 (2022).","DOI":"10.3390\/antibiotics11091234"},{"key":"972_CR121","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1001\/jama.2023.4314","volume":"329","author":"T Louie","year":"2023","unstructured":"Louie, T. et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA 329, 1356\u20131366 (2023).","journal-title":"JAMA"},{"key":"972_CR122","doi-asserted-by":"crossref","unstructured":"Doug\u00e9 A, Ravinet A, Corriger A, Cabrespine A, Wasiak M, Pereira B, Sokol H, Nguyen S, Bay JO. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study). BMJ Open. 2023 May 2;13(5):e068480. doi: 10.1136\/bmjopen-2022-068480. PMID: 37130682; PMCID: PMC10163541.","DOI":"10.1136\/bmjopen-2022-068480"},{"key":"972_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000541656","volume":"40","author":"D Weber","year":"2024","unstructured":"Weber, D. et al. Fecal microbiota transfer in acute graft-versus-host disease following allogeneic stem cell transplantation. Visc. Med. 40, 1\u20136 (2024).","journal-title":"Visc. Med."},{"key":"972_CR124","doi-asserted-by":"crossref","unstructured":"Maini Rekdal, V. et al. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 364, eaau6323 (2019).","DOI":"10.1126\/science.aau6323"},{"key":"972_CR125","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1126\/science.1191175","volume":"330","author":"BD Wallace","year":"2010","unstructured":"Wallace, B. D. et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831\u2013835 (2010).","journal-title":"Science"},{"key":"972_CR126","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1126\/science.aah5043","volume":"357","author":"LT Geller","year":"2017","unstructured":"Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156\u20131160 (2017).","journal-title":"Science"},{"key":"972_CR127","first-page":"481","volume":"19","author":"H Baydoun","year":"2025","unstructured":"Baydoun, H. et al. What\u2019s new and what\u2019s next in fecal microbiota transplantation? Biologics 19, 481\u2013496 (2025).","journal-title":"Biologics"},{"key":"972_CR128","first-page":"484","volume":"29","author":"AN Gray","year":"2023","unstructured":"Gray, A. N. & DeFilipp, Z. Fecal microbiota transplantation for acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: expanding the horizon into pediatrics. Transpl. Cell. Ther. 29, 484\u2013491 (2023).","journal-title":"Transpl. Cell. Ther."},{"key":"972_CR129","doi-asserted-by":"crossref","unstructured":"Wu, X., Qin, W., & Tang, S. (2025). Analyzing the impact of threshold strategies on cancer treatment using non-smooth models. Math. Biosci. 390, 109559.","DOI":"10.1016\/j.mbs.2025.109559"},{"key":"972_CR130","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41587-020-0603-3","volume":"39","author":"A Almeida","year":"2021","unstructured":"Almeida, A. et al. A unified catalog of 204,938 reference genomes from the human gut microbiome. Nat. Biotechnol. 39, 105\u2013114 (2021).","journal-title":"Nat. Biotechnol."},{"key":"972_CR131","doi-asserted-by":"publisher","first-page":"e16394","DOI":"10.7717\/peerj.16394","volume":"11","author":"F Liao","year":"2023","unstructured":"Liao, F. et al. Comparative analysis of shotgun metagenomics and 16S rDNA sequencing of gut microbiota in migratory seagulls. PeerJ 11, e16394 (2023).","journal-title":"PeerJ"},{"key":"972_CR132","doi-asserted-by":"crossref","unstructured":"Cheng, X. et al. Fecal 16S rRNA sequencing and multi-compartment metabolomics revealed gut microbiota and metabolites interactions in APP\/PS1 mice. Comput. Biol. Med. 151, 106312 (2022).","DOI":"10.1016\/j.compbiomed.2022.106312"},{"key":"972_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-63254-x","volume":"14","author":"BA Kifle","year":"2024","unstructured":"Kifle, B. A. et al. Shotgun metagenomic insights into secondary metabolite biosynthetic gene clusters reveal taxonomic and functional profiles of microbiomes in natural farmland soil. Sci. Rep. 14, 15096 (2024).","journal-title":"Sci. Rep."},{"key":"972_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31502-1","volume":"13","author":"S Leviatan","year":"2022","unstructured":"Leviatan, S. et al. An expanded reference map of the human gut microbiome reveals hundreds of previously unknown species. Nat. Commun. 13, 3863 (2022).","journal-title":"Nat. Commun."},{"key":"972_CR135","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s00253-024-13384-z","volume":"108","author":"D Go","year":"2024","unstructured":"Go, D. et al. Integration of metabolomics and other omics: from microbes to microbiome. Appl. Microbiol. Biotechnol. 108, 538 (2024).","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"972_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00823-6","volume":"11","author":"J Josephs-Spaulding","year":"2025","unstructured":"Josephs-Spaulding, J. et al. Metatranscriptomics-based metabolic modeling of patient-specific urinary microbiome during infection. npj Biofilms Microbiomes 11, 183 (2025).","journal-title":"npj Biofilms Microbiomes"},{"key":"972_CR137","doi-asserted-by":"publisher","first-page":"113865","DOI":"10.1016\/j.foodres.2023.113865","volume":"177","author":"S Xiong","year":"2024","unstructured":"Xiong, S. et al. Integrated metatranscriptomics and metabolomics reveal microbial succession and flavor formation mechanisms during the spontaneous fermentation of Laotan Suancai. Food Res. Int. 177, 113865 (2024).","journal-title":"Food Res. Int."},{"key":"972_CR138","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3324\/haematol.2023.284138","volume":"109","author":"SA P\u00f6tgens","year":"2024","unstructured":"P\u00f6tgens, S. A. et al. Gut microbiome alterations at acute myeloid leukemia diagnosis are associated with muscle weakness and anorexia. Haematologica 109, 3194\u20133208 (2024).","journal-title":"Haematologica"},{"key":"972_CR139","doi-asserted-by":"crossref","unstructured":"Lou, Y. et al. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS\/MS and its application in the clinical determination in patients with tumors associated with overactive bladder. J. Pharm. Biomed. Anal. 240, 115937 (2024).","DOI":"10.1016\/j.jpba.2023.115937"},{"key":"972_CR140","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/febs.17124","volume":"292","author":"M Jans","year":"2025","unstructured":"Jans, M. & Vereecke, L. A guide to germ-free and gnotobiotic mouse technology to study health and disease. FEBS J. 292, 1228\u20131251 (2025).","journal-title":"FEBS J."},{"key":"972_CR141","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1089\/ars.2022.0039","volume":"37","author":"X Wang","year":"2022","unstructured":"Wang, X., Wu, C. & Wei, H. Humanized germ-free mice for investigating the intervention effect of commensal microbiome on cancer immunotherapy. Antioxid. Redox Signal. 37, 1291\u20131302 (2022).","journal-title":"Antioxid. Redox Signal."},{"key":"972_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00786-8","volume":"11","author":"W Lei","year":"2025","unstructured":"Lei, W. et al. Gut microbiota shapes cancer immunotherapy responses. npj Biofilms Microbiomes 11, 143 (2025).","journal-title":"npj Biofilms Microbiomes"},{"key":"972_CR143","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1200\/JCO.22.02366","volume":"41","author":"A Rashidi","year":"2023","unstructured":"Rashidi, A. et al. Randomized double-blind Phase II trial of fecal microbiota transplantation versus placebo in allogeneic hematopoietic cell transplantation and AML. J. Clin. Oncol. 41, 5306\u20135319 (2023).","journal-title":"J. Clin. Oncol."},{"key":"972_CR144","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","volume":"7","author":"SMD Baunwall","year":"2022","unstructured":"Baunwall, S. M. D. et al. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol. Hepatol. 7, 1083\u20131091 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"972_CR145","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/ibd\/izac135","volume":"29","author":"N El Hage Chehade","year":"2023","unstructured":"El Hage Chehade, N. et al. Efficacy of fecal microbiota transplantation in the treatment of active ulcerative colitis: a systematic review and meta-analysis of double-blind randomized controlled trials. Inflamm. Bowel Dis. 29, 808\u2013817 (2023).","journal-title":"Inflamm. Bowel Dis."},{"key":"972_CR146","doi-asserted-by":"publisher","first-page":"e100086","DOI":"10.1136\/egastro-2024-100086","volume":"2","author":"C Prosty","year":"2024","unstructured":"Prosty, C. et al. Causal role of the gut microbiome in certain human diseases: a narrative review. eGastroenterology 2, e100086 (2024).","journal-title":"eGastroenterology"},{"key":"972_CR147","doi-asserted-by":"crossref","unstructured":"Sherwani, M. K. et al. Multi-omics time-series analysis in microbiome research: a systematic review. Brief. Bioinform. 26, bbaf502 (2025).","DOI":"10.1093\/bib\/bbaf502"},{"key":"972_CR148","doi-asserted-by":"publisher","first-page":"e2522740","DOI":"10.1001\/jamanetworkopen.2025.22740","volume":"8","author":"MH Woodworth","year":"2025","unstructured":"Woodworth, M. H. et al. Microbiota transplantation among patients receiving long-term care: the Sentinel REACT Nonrandomized Clinical Trial. JAMA Netw. Open 8, e2522740\u2013e2522740 (2025).","journal-title":"JAMA Netw. Open"},{"key":"972_CR149","doi-asserted-by":"crossref","unstructured":"Kobel, C. et al. Integrating host and microbiome biology using holo-omics. Mol. Omics 20, 438\u2013452 (2024).","DOI":"10.1039\/D4MO00017J"},{"key":"972_CR150","doi-asserted-by":"publisher","first-page":"101414","DOI":"10.1016\/j.isci.2020.101414","volume":"23","author":"L Nyholm","year":"2020","unstructured":"Nyholm, L. et al. Holo-Omics: integrated host-microbiota multi-omics for basic and applied biological research. iScience 23, 101414 (2020).","journal-title":"iScience"},{"key":"972_CR151","doi-asserted-by":"publisher","first-page":"100820","DOI":"10.1016\/j.crmeth.2024.100820","volume":"4","author":"I Odriozola","year":"2024","unstructured":"Odriozola, I. et al. A practical introduction to holo-omics. Cell Rep. Methods 4, 100820 (2024).","journal-title":"Cell Rep. Methods"},{"key":"972_CR152","doi-asserted-by":"crossref","unstructured":"Li, F., Tian, J., Zhang, L., He, H., & Song, D. A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1). Biomed. Pharm. Biomed. Pharm. 178, 117225 (2024).","DOI":"10.1016\/j.biopha.2024.117225"},{"key":"972_CR153","doi-asserted-by":"crossref","unstructured":"Li, W., Wang, S., Xu, J. & Xiang, J. Inferring Latent MicroRNA-Disease Associations on a Gene-Mediated Tripartite Heterogeneous Multiplexing Network. IEEE\/ACM Trans. Comput. Biol. Bioinform. 19(6), 3190\u20133201 (2022).","DOI":"10.1109\/TCBB.2022.3143770"},{"key":"972_CR154","doi-asserted-by":"publisher","first-page":"e39782","DOI":"10.1097\/MD.0000000000039782","volume":"103","author":"X Li","year":"2024","unstructured":"Li, X. et al. Metabolomics for hematologic malignancies: advances and perspective. Medicine 103, e39782 (2024).","journal-title":"Medicine"},{"key":"972_CR155","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713\u2013723 (2022).","journal-title":"Nat. Med."},{"key":"972_CR156","doi-asserted-by":"publisher","first-page":"2229567","DOI":"10.1080\/19490976.2023.2229567","volume":"15","author":"S Habibi","year":"2023","unstructured":"Habibi, S. & Rashidi, A. Fecal microbiota transplantation in hematopoietic cell transplant and cellular therapy recipients: lessons learned and the path forward. Gut Microbes 15, 2229567 (2023).","journal-title":"Gut Microbes"},{"key":"972_CR157","doi-asserted-by":"publisher","first-page":"e70143","DOI":"10.1002\/cam4.70143","volume":"13","author":"H Zhao","year":"2024","unstructured":"Zhao, H. et al. Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: a randomized, controlled, Phase 2 study. Cancer Med. 13, e70143 (2024).","journal-title":"Cancer Med."},{"key":"972_CR158","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41579-018-0053-9","volume":"16","author":"A Dart","year":"2018","unstructured":"Dart, A. Gut microbiota bile acid metabolism controls cancer immunosurveillance. Nat. Rev. Microbiol. 16, 453\u2013453 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"972_CR159","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.3389\/fimmu.2025.1638352","volume":"16","author":"Y Tong","year":"2025","unstructured":"Tong, Y. & Lou, X. Interplay between bile acids, gut microbiota, and the tumor immune microenvironment: mechanistic insights and therapeutic strategies. Front. Immunol. 16, 2025 (2025).","journal-title":"Front. Immunol."},{"key":"972_CR160","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.immuni.2022.01.006","volume":"55","author":"K Hezaveh","year":"2022","unstructured":"Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324\u2013340.e8 (2022).","journal-title":"Immunity"},{"key":"972_CR161","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/metabo13111166","volume":"13","author":"Y Hou","year":"2023","unstructured":"Hou, Y., Li, J. & Ying, S. Tryptophan metabolism and gut microbiota: a novel regulatory axis integrating the microbiome, immunity, and cancer. Metabolites 13, 1166 (2023).","journal-title":"Metabolites"},{"key":"972_CR162","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1126\/science.1235872","volume":"341","author":"HJ Haiser","year":"2013","unstructured":"Haiser, H. J. et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295\u2013298 (2013).","journal-title":"Science"},{"key":"972_CR163","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/cpt.3077","volume":"115","author":"AL Degraeve","year":"2024","unstructured":"Degraeve, A. L. et al. Tacrolimus pharmacokinetics is associated with gut microbiota diversity in kidney transplant patients: results from a pilot cross-sectional study. Clin. Pharmacol. Ther. 115, 104\u2013115 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"972_CR164","doi-asserted-by":"crossref","unstructured":"Microbial inosine promotes immune-checkpoint blockade response in mice. Cancer Discov. 10, 1439 (2020).","DOI":"10.1158\/2159-8290.CD-RW2020-120"},{"key":"972_CR165","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","volume":"30","author":"A Elkrief","year":"2019","unstructured":"Elkrief, A. et al. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann. Oncol. 30, 1572\u20131579 (2019).","journal-title":"Ann. Oncol."},{"key":"972_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0775-x","volume":"7","author":"DJ Pinato","year":"2019","unstructured":"Pinato, D. J. et al. Antibiotic therapy and outcome from immune-checkpoint inhibitors. J. Immunother. Cancer 7, 287 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"972_CR167","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science 359, 91\u201397 (2018).","journal-title":"Science"},{"key":"972_CR168","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/annonc\/mdu106","volume":"25","author":"MG Redman","year":"2014","unstructured":"Redman, M. G., Ward, E. J. & Phillips, R. S. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann. Oncol. 25, 1919\u20131929 (2014).","journal-title":"Ann. Oncol."},{"key":"972_CR169","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1017\/ice.2021.261","volume":"43","author":"FS Tom","year":"2022","unstructured":"Tom, F. S. et al. Infectious complications of probiotic use: a matched case-control study. Infect. Control Hosp. Epidemiol. 43, 1498\u20131500 (2022).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"972_CR170","doi-asserted-by":"crossref","unstructured":"Ma, L., Tu, H. & Chen, T. Postbiotics in human health: a narrative review. Nutrients 15, 291 (2023).","DOI":"10.3390\/nu15020291"},{"key":"972_CR171","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41575-021-00440-6","volume":"18","author":"S Salminen","year":"2021","unstructured":"Salminen, S. et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat. Rev. Gastroenterol. Hepatol. 18, 649\u2013667 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"972_CR172","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.phrs.2018.10.029","volume":"139","author":"KW Cheng","year":"2019","unstructured":"Cheng, K. W. et al. Pharmacological inhibition of bacterial \u03b2-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. Pharm. Res. 139, 41\u201349 (2019).","journal-title":"Pharm. Res."},{"key":"972_CR173","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/nu17182973","volume":"17","author":"F McCullough","year":"2025","unstructured":"McCullough, F., Cheung, J. & Miller, L. J. A systematic review evaluating the impact of fibre supplementation on gut health and other clinical outcomes in adults with haematological malignancies during haematopoietic stem cell transplantation. Nutrients 17, 2973 (2025).","journal-title":"Nutrients"},{"key":"972_CR174","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41591-023-02587-y","volume":"29","author":"MM Riwes","year":"2023","unstructured":"Riwes, M. M. et al. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat. Med. 29, 2805\u20132813 (2023).","journal-title":"Nat. Med."},{"key":"972_CR175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.03.002","volume":"199","author":"AN Chamseddine","year":"2019","unstructured":"Chamseddine, A. N. et al. Intestinal bacterial \u03b2-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. Pharmacol. Ther. 199, 1\u201315 (2019).","journal-title":"Pharmacol. Ther."},{"key":"972_CR176","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fnut.2022.993668","volume":"9","author":"E Muratore","year":"2022","unstructured":"Muratore, E. et al. Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients. Front. Nutr. 9, 2022 (2022).","journal-title":"Front. Nutr."},{"key":"972_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82726-y","volume":"11","author":"F Durazzi","year":"2021","unstructured":"Durazzi, F. et al. Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Sci. Rep. 11, 3030 (2021).","journal-title":"Sci. Rep."},{"key":"972_CR178","doi-asserted-by":"publisher","first-page":"100391","DOI":"10.1016\/j.crmeth.2022.100391","volume":"3","author":"M Usyk","year":"2023","unstructured":"Usyk, M. et al. Comprehensive evaluation of shotgun metagenomics, amplicon sequencing, and harmonization of these platforms for epidemiological studies. Cell Rep. Methods 3, 100391 (2023).","journal-title":"Cell Rep. Methods"},{"key":"972_CR179","first-page":"5","volume":"12","author":"V Aguiar-Pulido","year":"2016","unstructured":"Aguiar-Pulido, V. et al. Metagenomics, metatranscriptomics, and metabolomics approaches for microbiome analysis. Evol. Bioinform. Online 12, 5\u201316 (2016).","journal-title":"Evol. Bioinform. Online"},{"key":"972_CR180","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1039\/D3MO00089C","volume":"19","author":"M Arikan","year":"2023","unstructured":"Arikan, M. & Muth, T. Integrated multi-omics analyses of microbial communities: a review of the current state and future directions. Mol. Omics 19, 607\u2013623 (2023).","journal-title":"Mol. Omics"},{"key":"972_CR181","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1002\/imt2.73","volume":"2","author":"N Zhang","year":"2023","unstructured":"Zhang, N. et al. Applying multi-omics toward tumor microbiome research. iMeta 2, e73 (2023).","journal-title":"iMeta"},{"key":"972_CR182","doi-asserted-by":"publisher","first-page":"670336","DOI":"10.3389\/fmicb.2021.670336","volume":"12","author":"D Peterson","year":"2021","unstructured":"Peterson, D. et al. Comparative analysis of 16S rRNA gene and metagenome sequencing in pediatric gut microbiomes. Front. Microbiol. 12, 670336 (2021).","journal-title":"Front. Microbiol."}],"container-title":["npj Biofilms and Microbiomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00972-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:03:48Z","timestamp":1782090228000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41522-026-00972-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1038\/s41522-026-00972-2","relation":{},"ISSN":["2055-5008"],"issn-type":[{"value":"2055-5008","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"29 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}